Carregant...
Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
BACKGROUND: Lanadelumab demonstrated efficacy in preventing hereditary angioedema (HAE) attacks in the phase 3 HELP Study. OBJECTIVE: To assess time to onset of effect and long‐term efficacy of lanadelumab, based on exploratory findings from the HELP Study. METHODS: Eligible patients with HAE type I...
Guardat en:
| Publicat a: | Allergy |
|---|---|
| Autors principals: | , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7689768/ https://ncbi.nlm.nih.gov/pubmed/32452549 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/all.14416 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|